TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01050608

Intervention type: DEVICE
Intervention: Body worn alcohol gel dispenser
Description: Records hand hygiene events of provider and tabulates on the group level.

Intervention type: DRUG
Intervention: 62% ethanol based hand cleanser
Description: CDC based guidelines with regard to utilization in the health care environment the nest

Intervention type: BEHAVIORAL
Intervention: Educational component with regard to teaching CDC guidelines
Description: 12 minute education prior to deploying device for all providers.

Intervention type: BEHAVIORAL
Intervention: Provider and group feedback
Description: Provide feedback with regard to expected hand hygiene goals to providers and reported anonymous group results based on recorded information.
Study: NCT01381250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavior therapy
Description: The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur \& Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
Study: NCT02359747

Intervention type: GENETIC
Intervention: Polymerase Chain Reaction and Whole Genome Amplification
Description: Polymerase Chain Reaction and Whole Genome Amplification
Study: NCT00796679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: oral paricalcitol capsule 1 microgram once daily if iPTH \<500pg/mL or 2 microgram once daily if iPTH \>=500pg/mL. Thereafter, dose titration in 1 microgram decrement will be done based on safety reasons (that is, for low PTH or high calcium and phosphorus level). The duration of treatment will be for 1 year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paricalcitol
Description: oral paricalcitol capsule 1 microgram once daily if iPTH \<500pg/mL or 2 microgram once daily if iPTH \>=500pg/mL. Thereafter, dose titration in 1 microgram decrement will be done based on safety reasons (that is, for low PTH or high calcium and phosphorus level). The duration of treatment will be for 1 year.
Study: NCT00686075

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-534, Cohort 1
Description: Participants aged 6 to less than (\<) 24 months will receive MEDI-534, 10\^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Cohort 1
Description: Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-534, Cohort 2
Description: Participants aged 6 to \<24 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Cohort 2
Description: Participants aged 6 to \<24 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-534, Cohort 3
Description: Participants aged 2 months will receive MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Cohort 3
Description: Participants aged 2 months will receive placebo matched to MEDI-534, 10\^4 TCID50 by intranasal route at Month 0, 2, and 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-534, Cohort 4
Description: Participants aged 2 months will receive MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Cohort 4
Description: Participants aged 2 months will receive placebo matched to MEDI-534, 10\^5 TCID50 by intranasal route at Month 0, 2, and 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-534, Cohort 5
Description: Participants aged 2 months will receive MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Cohort 5
Description: Participants aged 2 months will receive placebo matched to MEDI-534, 10\^6 TCID50 by intranasal route at Month 0, 2, and 4.
Study: NCT03457467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment
Study: NCT03250559

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous nephrolithotomy
Description: Endoscopic kidney stone extraction technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous nephrolithotomy
Description: Endoscopic kidney stone extraction technique.
Study: NCT03254381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Six months of thrice-weekly resistance training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down). Classes will be group classes, with up to five participants in each.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance and Tone Training
Description: Six months of thrice-weekly stretching and relaxation exercises. Each session will be 60 minutes. Classes will be group classes, with up to five participants in each.
Study: NCT03107312

Intervention type: PROCEDURE
Intervention: Single blood sample collection
Description: Collection of single blood sample of 10 ml volume by venepuncture

Intervention type: PROCEDURE
Intervention: Single blood sample collection
Description: Collection of single blood sample of 10 ml volume by venepuncture
Study: NCT00574912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single dose of Placebo injected s/c at 8am and monitor blood glucose over 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine 0.5 u/kg body wt SC
Description: 8 weeks later, a differing dose (0.5, 1.0, 1.5, 2.0 u/kg body wt.) of Insulin Glargine and monitoring over a 24 hour period each separated by 8 weeks (5 separate study visits)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine 1.0 u/kg body wt SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine 1.5 u/kg body wt SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine 2.0 u/kg body wt SC
Study: NCT02838654

Intervention type: PROCEDURE
Intervention: cervical epidural injection
Description: sensitivity, specificity, positive predictive value, negative predictive value
Study: NCT00589329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythromycin and metronidazole (antibiotics)
Description: Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV and pill placebo
Study: NCT04180163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Lanadelumab solution, SC
Study: NCT01163630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole/ASA Fixed Dose Combination (FDC)
Description: esomeprazole 20 mg/ASA 81 mg oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole/ASA Fixed Dose Combination (FDC)
Description: esomeprazole 20 mg/ASA 81 mg oral capsule
Study: NCT02903992

Intervention type: RADIATION
Group type: OTHER
Intervention: Dual-energy X-ray absorptiometry (DXA)
Description: Patients with at least one Fried criteria will have a Dual-energy X-ray absorptiometry (DXA) to measure lean muscle mass adjusted for body mass index. As part of the usual care in the Frailty Clinic patients will also have a clinical examination, a standard biological sample (requiring 15 ml of blood); an evaluation of the cognitive and functional performances, of their medico-economic situation and lifestyle.
Study: NCT02132637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Peglispro
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SQ
Study: NCT04328857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pseudoelastic orthosis
Description: The subject will be given specific physiotherapy including activities oriented to multimodal exploration and refinement of gross and fine motor skills, customized according to the functional status of the individual patient.
Study: NCT00806286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS7017 tablets
Description: CS7017 tablets, strength 0.25 mg, two tablets, two times daily for twenty-five to thirty months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous (IV), 200 mg/m\^2, once every three weeks for up to 18 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous (IV), 200 mg/m\^2, once every three weeks for up to 18 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV, area under the curve (AUC) of 6, once every three weeks for up to 18 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: IV, area under the curve (AUC) of 6, once every three weeks for up to 18 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo tablets matching CS-7017 tablets
Study: NCT02395952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboxymethylcellulose sodium
Description: frequent topical lubrication with artificial tears

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue Oasys Bandage Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambiodisk

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prokera
Study: NCT01545661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sputum induction
Description: Ultrasonic nebulisation 3% hypertonic saline nebulised for duration of 20 mins

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard routine expectorated sputum
Description: Patients in the control group are trained by the research staff to produce sputum but no device is utilized. Sputum is spontaneously expectorated where possible
Study: NCT00845819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhEGF + povidone iodine, chlorhexidine, & nystatin
Description: Topical application of 50 µg/mL rhEGF solution twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%) \& nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC\>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of rhEGF, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + povidone iodine, chlorhexidine, & nystatin
Description: Topical application of placebo drug twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%), and nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC\>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of placebo drug, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva.
Study: NCT04727814

Intervention type: OTHER
Intervention: Computer-aided detection system overlaid colonoscopy videos analysis
Description: Analysis of computer-aided detection system overlaid videos from colonoscopies performed with water exchange or air insufflation method.

Intervention type: OTHER
Intervention: Computer-aided detection system overlaid colonoscopy videos analysis
Description: Analysis of computer-aided detection system overlaid videos from colonoscopies performed with water exchange or air insufflation method.
Study: NCT00289536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic factor, recombinant, manufactured protein-free
Description: 15 IU/kg rAHF-PFM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic factor, recombinant, manufactured protein-free
Description: 30 IU/kg rAHF-PFM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic factor, recombinant, manufactured protein-free
Description: 50 IU/kg rAHF-PFM
Study: NCT05922475

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Post-exercise protein group consumed protein immediately after exercise sessions.~Pre-sleep protein group consumed protein 30 minutes before sleep.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Post-exercise protein group consumed protein immediately after exercise sessions.~Pre-sleep protein group consumed protein 30 minutes before sleep.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Resistance exercise training only group did not consume supplemental protein.
Study: NCT02335736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins releasing hormone antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins releasing hormone antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins releasing hormone antagonist
Study: NCT02116959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study: NCT00801580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin liposomal
Description: * Cyclophosphamide~* Mesna~* Methotrexate~* Doxorubicin liposomal~* Vincristine~* Dexamethasone~* Rituximab~* Cytarabine
Study: NCT03024658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positive end expiratory pressure (PEEP)
Description: Positive end expiratory pressure was applied using anesthesia machine at the time of induction in the patients undergoing laparoscopic bariatric surgery
Study: NCT04099550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RT-CGM
Description: The group was monitored blood glucose initial 1-week with a RT-CGM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMBG
Description: The group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.
Study: NCT00283023

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oligodendrocyte progenitor cell culture/craniotomy
Description: Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
Study: NCT02739945

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cubital tunnel release
Description: The ulnar nerve is decompressed proximally at the intramuscular septum, decompressed more distally through the cubital tunnel and then exposed between the two heads of the flexor carpi ulnaris muscle. Care is taken to ensure that any point that might compress the ulnar nerve either proximally or distally is evaluated.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cubital tunnel release
Description: The ulnar nerve is decompressed proximally at the intramuscular septum, decompressed more distally through the cubital tunnel and then exposed between the two heads of the flexor carpi ulnaris muscle. Care is taken to ensure that any point that might compress the ulnar nerve either proximally or distally is evaluated.
Study: NCT01642459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same direction cannulation
Description: The puncture direction of the arterial needle is same as the blood flow in every hemodialysis session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opposite direction cannulation
Description: The puncture direction of the arterial needle is opposite to the blood flow in every hemodialysis session.
Study: NCT02798744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 25mg once daily to be taken orally for the duration of the study (24 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 25mg once daily to be taken orally for the duration of the study (24 weeks)
Study: NCT01989988

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LMGB

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LRYGB

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SADJB
Study: NCT03542955

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActiPatch
Description: A Pulsed Shortwave Therapy Device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoricoxib 60 mg
Description: nonsteroidal anti-inflammatory drug used as standard therapy
Study: NCT02650479

Intervention type: DRUG
Group type: OTHER
Intervention: Exenatide
Description: 6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 6 hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 6 hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg oral dose moxifloxacin within 1 min of start of infusion of exenatide

Intervention type: DRUG
Group type: OTHER
Intervention: Palonosetron
Description: 0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: 0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: 0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide
Study: NCT02778659

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
Study: NCT02650479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: 0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide
Study: NCT02330315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial ultrasound (TUS)
Description: Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial ultrasound (TUS)
Description: Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
Study: NCT01775852

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT-IM
Description: 1 hour discussion about migraine management (IM) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). IM covers symptoms and triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
Study: NCT01090830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat, carboplatin, paclitaxel and bevacizumab
Description: Induction therapy will include 6 cycles of 5-days of medication administration followed by a 16 day rest period. Belinostat will be given once a day for 5 days total. Three dose levels will be evaluated (600mg/kg, 800 mg/kg, and 1000 mg/kg). In addition, participants will receive fixed doses of intravenous carboplatin (AUC 6), Paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) once on day 3 of each cycle. Serial disease status evaluations will be done throughout the study.~In the absence of significant toxicity or disease progression, participants may continue with a maintenance regimen of bevacizumab and Belinostat for an additional 6 cycles. The dose of Belinostat received during maintenance will be that tolerated in the initial 6 cycles.